David Peng

8PUBLICATIONS
118CO-AUTHORS
Molecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 11, 2026
CDK8 remodels the tumor microenvironment and promotes resistance to KRAS<sup>G12D</sup> inhibitors and daraxonrasib in PDAC.

|Sep 18, 2025
KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer.

Yongkun Wei, Minghui Liu, Er-Yen Yen

|Sep 03, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.

Kathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker

|May 03, 2023
<i>In vivo</i> metabolomics identifies CD38 as an emergent vulnerability in <i>LKB1</i> -mutant lung cancer.

Jiehui Deng, David H Peng, David Fenyo

|May 11, 2021
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.

David H Peng, B Leticia Rodriguez, Lixia Diao

|Sep 04, 2020
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.

Monique B Nilsson, Huiying Sun, Jacqulyne Robichaux

Pageof 2

Frequent Collaborators

4 joint publications

Don L Gibbons

3 joint publications

Lixia Diao

3 joint publications

Timothy P Heffernan

2 joint publications

Raghu Kalluri